Mackenzie Financial’s Aclaris Therapeutics ACRS Stock Holding History

Mackenzie Financial’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$800K	Buy	+213,405	New	+$720K	﹤0.01%	1121

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Mackenzie Financial's ACRS Position: Q1 2026 in Review

Mackenzie Financial opened a new position in Aclaris Therapeutics (ACRS) in Q1 2026: 213,405 shares worth $800K. The stake represents ﹤0.01% of the portfolio and ranks #1121 among its holdings.

136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

Mackenzie Financial held 213,405 shares of Aclaris Therapeutics worth $800K as of Q1 2026.
Aclaris Therapeutics was a new Mackenzie Financial position in Q1 2026.
Aclaris Therapeutics made up ﹤0.01% of Mackenzie Financial's portfolio in Q1 2026, its #1121 holding.
136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.